Gap finder

Search review questions

Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.

Population

Intervention or exposure

Comparison

Outcome

Any field or review title

Field or topic

Source

Review versions

75,239 questions in 5,342 reviews

current versions

No studies 15,213 · 20.2%Ungraded 10,323 · 13.7%Very low 17,528 · 23.3%Low 17,951 · 23.9%Moderate 11,190 · 14.9%High 3,034 · 4%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Question	Effect	Evidence	Status / GRADE
Renin‐angiotensin system inhibition vs other supportive care treatment > 50% increase in SCr · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	RR 0.23 [0.07, 0.7]	1 study · 44 participants	Low
Renin‐angiotensin system inhibition vs other supportive care treatment Proteinuria · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	no estimate extracted	3 studies · 168 participants	Moderate
Tonsillectomy plus standard care vs standard care Death (any cause) · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	no estimate extracted	NR	No studies
Tonsillectomy plus standard care vs standard care Kidney failure · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	no estimate extracted	NR	No studies
Tonsillectomy plus standard care vs standard care Remission of proteinuria · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	RR 1.9 [1.45, 2.47]	2 studies · 143 participants	Low
Tonsillectomy plus standard care vs standard care Remission of haematuria (microscopic) · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	RR 1.93 [1.47, 2.53]	2 studies · 143 participants	Low
Tonsillectomy plus standard care vs standard care Relapse of haematuria (macroscopic) · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	RR 1.33 [0.8, 2.23]	1 study · 32 participants	Very low
Renin‐angiotensin system inhibition vs placebo or no treatment Kidney failure or doubling of SCr · people with IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	RR 0.25 [0.03, 2.21]	1 study · 109 participants	Low
Tonsillectomy plus standard care vs standard care Relapse of proteinuria · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	RR 0.7 [0.57, 0.85]	1 study · 73 participants	Low
Tonsillectomy plus standard care vs standard care > 50% increase in SCr · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	no estimate extracted	NR	No studies
Tonsillectomy plus standard care vs standard care Proteinuria · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	no estimate extracted	2 studies · 69 participants	Low
Renin‐angiotensin system inhibition vs placebo or no treatment Remission of proteinuria: complete remission · people with IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	RR 5.29 [0.27, 102.49]	1 study · 33 participants	Low
Renin‐angiotensin system inhibition vs placebo or no treatment Remission of haematuria · people with IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	no estimate extracted	NR	No studies
Renin‐angiotensin system inhibition vs placebo or no treatment Relapse of proteinuria · people with IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	no estimate extracted	NR	No studies
Renin‐angiotensin system inhibition vs placebo or no treatment > 50% increase in SCr · people with IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	no estimate extracted	NR	No studies
Renin‐angiotensin system inhibition vs placebo or no treatment Proteinuria · people with IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	no estimate extracted	4 studies · 199 participants	Moderate
Renin‐angiotensin system inhibition vs other supportive care treatment Death · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	no estimate extracted	NR	No studies
Renin‐angiotensin system inhibition vs other supportive care treatment Kidney failure · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	RR 0.2 [0.01, 3.88]	1 study · 34 participants	Very low
Evening vs morning dosing regimen All‐cause mortality · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80… Evening versus morning dosing regimen drug therapy for hypertension (2024) · Cochrane	RR 0.49 [0.04, 5.42]	1 study · 735 participants	Very low
Evening vs morning dosing regimen Cardiovascular mortality (time points not specified) · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80… Evening versus morning dosing regimen drug therapy for hypertension (2024) · Cochrane	no estimate extracted	NR	No studies
Evening vs morning dosing regimen Cardiovascular morbidity (stroke, myocardial infarction, congestive heart failure, aortic aneurysm) (time points not specified) · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80… Evening versus morning dosing regimen drug therapy for hypertension (2024) · Cochrane	no estimate extracted	NR	No studies
Evening vs morning dosing regimen Serious adverse events · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80… Evening versus morning dosing regimen drug therapy for hypertension (2024) · Cochrane	RR 1.17 [0.53, 2.57]	2 studies · 833 participants	Very low
Evening vs morning dosing regimen Overall adverse events · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80… Evening versus morning dosing regimen drug therapy for hypertension (2024) · Cochrane	RR 0.89 [0.67, 1.2]	7 studies · 1541 participants	Very low
Evening vs morning dosing regimen Withdrawals from treatment due to adverse events · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80… Evening versus morning dosing regimen drug therapy for hypertension (2024) · Cochrane	RR 0.76 [0.47, 1.23]	7 studies · 1777 participants	Very low
Magnesium sulphate vs placebo (outcomes Death (fetal, neonatal, or later (up to 2 years' corrected age))** · women at risk of preterm birth (< 34 weeks' gestation) Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus (2024) · Cochrane	RR 0.96 [0.82, 1.13]	6 studies · 6759 participants	Moderate
Magnesium sulphate vs placebo (outcomes Death or cerebral palsy (up to school age)** · women at risk of preterm birth (< 34 weeks' gestation) Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus (2024) · Cochrane	RR 0.9 [0.67, 1.2]	1 study · 503 participants	Low
Magnesium sulphate vs placebo (outcomes Major neurodevelopmental disability (school age)** · women at risk of preterm birth (< 34 weeks' gestation) Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus (2024) · Cochrane	RR 0.92 [0.53, 1.62]	2 studies · 940 participants	Very low
Magnesium sulphate vs placebo (outcomes Death or major neurodevelopmental disability (up to school age)** · women at risk of preterm birth (< 34 weeks' gestation) Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus (2024) · Cochrane	RR 0.81 [0.59, 1.12]	1 study · 503 participants	Low
Magnesium sulphate vs placebo (outcomes Severe maternal outcome potentially related to treatment (death, respiratory arrest, or cardiac arrest)** · women at risk of preterm birth (< 34 weeks' gestation) Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus (2024) · Cochrane	RR 0.32 [0.01, 7.92]	4 studies · 5300 participants	Low
Magnesium sulphate vs placebo (outcomes Adverse effects severe enough to stop treatment** · women at risk of preterm birth (< 34 weeks' gestation) Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus (2024) · Cochrane	RR 3.21 [1.88, 5.48]	3 studies · 4736 participants	Moderate
Magnesium sulphate vs placebo (outcomes Mode of birth (caesarean section)** · women at risk of preterm birth (< 34 weeks' gestation) Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus (2024) · Cochrane	RR 0.96 [0.91, 1.02]	5 studies · 5861 participants	Moderate
Magnesium sulphate vs placebo (outcomes Postpartum haemorrhage** · women at risk of preterm birth (< 34 weeks' gestation) Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus (2024) · Cochrane	RR 0.94 [0.8, 1.09]	2 studies · 2495 participants	Moderate
Magnesium sulphate vs placebo (outcomes Breastfeeding at hospital discharge** · women at risk of preterm birth (< 34 weeks' gestation) Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus (2024) · Cochrane	no estimate extracted	NR	No studies
Magnesium sulphate vs placebo (outcomes Women’s views of treatment** · women at risk of preterm birth (< 34 weeks' gestation) Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus (2024) · Cochrane	no estimate extracted	NR	No studies
Magnesium sulphate vs placebo (outcomes Cerebral palsy (up to 2 years' corrected age)** · women at risk of preterm birth (< 34 weeks' gestation) Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus (2024) · Cochrane	RR 0.71 [0.57, 0.89]	6 studies · 6107 participants	High
Magnesium sulphate vs placebo (outcomes Death or cerebral palsy (up to 2 years' corrected age)** · women at risk of preterm birth (< 34 weeks' gestation) Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus (2024) · Cochrane	RR 0.87 [0.77, 0.98]	6 studies · 6481 participants	High
Magnesium sulphate vs placebo (outcomes Major neurodevelopmental disability (up to 2 years' corrected age)** · women at risk of preterm birth (< 34 weeks' gestation) Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus (2024) · Cochrane	RR 1.09 [0.83, 1.44]	1 study · 987 participants	Moderate
Magnesium sulphate vs placebo (outcomes Death or major neurodevelopmental disability (up to 2 years' corrected age)** · women at risk of preterm birth (< 34 weeks' gestation) Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus (2024) · Cochrane	RR 0.95 [0.85, 1.07]	3 studies · 4279 participants	Moderate
Magnesium sulphate vs placebo (outcomes Severe intraventricular haemorrhage (grade 3 or 4) (newborn/infant)** · women at risk of preterm birth (< 34 weeks' gestation) Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus (2024) · Cochrane	RR 0.76 [0.6, 0.98]	5 studies · 5885 participants	Moderate
Magnesium sulphate vs placebo (outcomes Chronic lung disease/bronchopulmonary dysplasia (newborn/infant)** · women at risk of preterm birth (< 34 weeks' gestation) Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus (2024) · Cochrane	RR 0.92 [0.77, 1.1]	5 studies · 6689 participants	Low
Magnesium sulphate vs placebo (outcomes Death (fetal, neonatal, or later (up to school age))** · women at risk of preterm birth (< 34 weeks' gestation) Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus (2024) · Cochrane	RR 0.82 [0.66, 1.02]	2 studies · 1758 participants	Low
Magnesium sulphate vs placebo (outcomes Cerebral palsy (school age)** · women at risk of preterm birth (< 34 weeks' gestation) Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus (2024) · Cochrane	RR 0.99 [0.69, 1.41]	2 studies · 1038 participants	Low
Summary of findings table ‐ Midwife continuity of care models vs other models of care Spontaneous vaginal birth (as defined by trial authors) · childbearing women and their infants (all) (critical outcomes) Midwife continuity of care models versus other models of care for childbearing women (2024) · Cochrane	RR 1.05 [1.03, 1.07]	15 studies · 17864 participants	Moderate
Summary of findings table ‐ Midwife continuity models vs other models of care Induction of labour · childbearing women and their infants (all) (important/secondary outcomes) Midwife continuity of care models versus other models of care for childbearing women (2024) · Cochrane	RR 0.92 [0.85, 1]	14 studies · 17666 participants	Low
Summary of findings table ‐ Midwife continuity models vs other models of care Instrumental vaginal birth (forceps/vacuum) · childbearing women and their infants (all) (important/secondary outcomes) Midwife continuity of care models versus other models of care for childbearing women (2024) · Cochrane	RR 0.89 [0.83, 0.96]	14 studies · 17769 participants	Moderate
Summary of findings table ‐ Midwife continuity models vs other models of care Episiotomy · childbearing women and their infants (all) (important/secondary outcomes) Midwife continuity of care models versus other models of care for childbearing women (2024) · Cochrane	RR 0.83 [0.77, 0.91]	15 studies · 17839 participants	Low
Summary of findings table ‐ Midwife continuity models vs other models of care Third or fourth degree tear · childbearing women and their infants (all) (important/secondary outcomes) Midwife continuity of care models versus other models of care for childbearing women (2024) · Cochrane	RR 1.1 [0.81, 1.49]	7 studies · 9437 participants	Very low
Summary of findings table ‐ Midwife continuity models vs other models of care Postpartum haemorrhage (as defined by trial authors) · childbearing women and their infants (all) (important/secondary outcomes) Midwife continuity of care models versus other models of care for childbearing women (2024) · Cochrane	RR 0.92 [0.82, 1.03]	11 studies · 14407 participants	Moderate
Summary of findings table ‐ Midwife continuity models vs other models of care Breastfeeding initiation · childbearing women and their infants (all) (important/secondary outcomes) Midwife continuity of care models versus other models of care for childbearing women (2024) · Cochrane	RR 1.06 [1, 1.12]	8 studies · 8575 participants	Low
Summary of findings table ‐ Midwife continuity models vs other models of care Maternal readmission within 28 days · childbearing women and their infants (all) (important/secondary outcomes) Midwife continuity of care models versus other models of care for childbearing women (2024) · Cochrane	RR 1.52 [0.78, 2.96]	1 study · 1195 participants	Very low